05.29.25 -- Key Considerations For Early-Stage CGT Companies When Selecting A CDMO

Explore strategies to optimize AAV manufacturing by reducing risk and balancing productivity, quality, and cost to meet the growing demands of gene therapy.

With real-world examples and a vision that challenges the prevailing norms of biotech commercialization, this conversation offers a powerful look at what it takes to reshape the future of healthcare.

T-cell lymphomas are a complex and increasingly prevalent group of cancers with poor survival outcomes and limited effective treatments, underscoring an urgent need for innovative therapies and novel targets.

Explore our full collection of case studies to discover how liposome technology is transforming drug delivery across a wide range of therapies.

When advanced therapy organizations place innovation at the heart of their strategy for overcoming supply chain challenges, they ultimately prioritize the most important stakeholder — the waiting patient.

Gain insight into these end-to-end plasmid DNA solutions, leveraging robust cGMP-compliant processes and single-use manufacturing platforms to accelerate your cell and gene therapy programs.

Leverage advanced elemental impurity testing methods to ensure the safety, compliance, and accuracy of your drug products throughout the manufacturing process.

By refining variables such as starting DNA, reagents, cell density, and media composition, organizations can improve rAAV process efficiency and scalability.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies.

Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from Suparna Sanyal, PhD, Head of Viral Vectors Commercial Development.